You are here

Global List Event

GMP and Regulatory Expectations for Early IND Products 2017

NetZealous DBA as GlobalCompliancePanel

 

Course "GMP and Regulatory Expectations for Early IND Products" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.

 

Overview:

 

This course will present, in one place, the regulations and guidelines that apply to early phase products. In some cases these will not be regulations, but needs that, if met, will increase the efficiency of activities as a product proceeds through the development process. The course will present these items in the order of product development from the point of R & D activities to the completion of Phase 2 clinical trials.

 

Why should you attend:

 

Any pharmaceutical worker who must deal with products both in early and latter phases of development should attend this course in order to be aware of the regulatory requirements that will affect operations dealing with these products. The modifications to the GMPs for early phase products have modified the GMPs in such a way as to reduce requirements to allow more efficient work. At the same time some of the things that may appear to have changed, have not, and the pharmaceutical worker should be aware of this.

 

Who will benefit:

 

  • Directors, Managers, Supervisors, and lead workers in Regulatory Affairs, Quality Assurance and Quality Control
  • Workers who will prepare GMP documents for early phase products as well as those who will review these documents
  • Regulatory affairs workers who will need to deal with submissions covering early phase products

 

 

Agenda:

Day 1 Schedule

 

Lecture 1:

Very Early Stages

  • The need for documentation of matters that will affect downstream work.
  • The effects of ICH Q8
    • Impact on R & D activities
    • Risk analysis and design control at this stage.

Lecture 2:

GLP requirements

  • Animal studies
    • Toxicology and pharmacokinetics.
  • Estimating the Maximum Safe Starting Dose
    • A review of the guidance document.

Lecture 3:

Early Pre-IND Studies

  • Understanding exploratory Studies
    • Definitions and the IND that will be withdrawn.
  • Orphan Drugs
  • Drugs studied under the Animal Rule
    • What they are and how to conduct the studies.

Lecture 4:

Meetings and Preparing for the IND

  • Information required for the Phase 1 IND
    • The CMC requirements that will be needed.
  • Pre-IND Meetings with FDA

 

Day 2 Schedule

 

Lecture 1:

GMPs for Phase 1 IND products

  • The scope of the guidance document
  • The second guidance document covering the GMPs.

Lecture 2:

GMPs for Phase 1 continued

  • A presentation covering what GMPs are required at this stage.
  • What has been omitted from the GMPs for Phase 1.

Lecture 3:

Requirements for Phase 2 INDs

  • The full GMPs resume, but do they?
  • Phase 2 studies and the transition to full GMPs.
  • CMC requirements.

Lecture 4:

Preparing for IND Meetings

  • Phase 1 meetings
  • Pre-phase 2 meetings
  • Phase 2 meetings

 

 

Speaker

Dr. Steven Kuwahara

Founder & Principal, GXP Biotechnology, LLC


Dr. Steven Kuwahara, Ph.D. is the Founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories. Steve has participated in the development of drugs and biologicals through all phases of clinical research and final product production.

 

 Location: Seoul, South Korea Date:  November 9th & 10th, 2017 and Time: 9:00 AM to 6:00 PM

Venue: WILL BE ANNOUNCED SOON, Seoul, South Korea

Price:

 

Price: $895.00 (Seminar Fee for One Delegate)

Register for 5 attendees   Price: $2,685.00   $4,475.00 You Save: $1,790.00 (40%)*

Register now and save $200. (Early Bird)

Until October 05, Early Bird Price: $895.00 From October 06 to November 07, Regular Price: $1,095.00

 Register for 10 attendees   Price: $4,922.00  $8,950.00 You Save: $4,028.00 (45%)*

 

Sponsorship Program benefits for “Quality Assurance Auditing for FDA Regulated Industry” seminar

At this seminar, world-renowned FDA Regulated Industry subject matter experts interact with CXO’s of various designations. Executives who carry vast experience about FDA Regulated Industry and Experts get down to discussing industry-related best practices, regulatory updates, changes in technologies, and much more relating to FDA Regulated Industry.

As a sponsor of these seminars, you get the opportunity to have your product and company reach out to C-Level executives in FDA Regulatory -related industries and become known among these elite executives and subject matter experts. Apart from being seen prominently at these globally held seminars, you also get talked about frequently in our correspondences with our experts and these participants.

For More Information- https://www.globalcompliancepanel.com/control/sponsorship 

 

Contact us today!

 

NetZealous LLC DBA GlobalCompliancePanel

john.robinson@globalcompliancepanel.com  

support@globalcompliancepanel.com 

Toll free: 1-800-447-9407

Phone: 1-510-584-9661

 Website: http://www.globalcompliancepanel.com

 

Registration Link - http://www.globalcompliancepanel.com/control/globalseminars/~product_id=901318SEMINAR?globaleventslist-November-2017-SEO

 

Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel/

Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/

Follow us on Twitter: https://twitter.com/GCPanel

 

 

Nov 2017
9
Nov 2017
10

Address details

Seoul, South Korea
Seoul, South Korea, 94010
United States

Location information

Seoul, South Korea